Antidepressants show upside in economic downturn

Antidepressants are looking to be big-time recession-busters. In spite of the cost of brand-name meds, Eli Lilly's Cymbalta has grown by leaps and bounds during the economic downturn, with second-quarter sales up by 14 percent year-over-year. And antidepressants in general haven't halted their upward trend, posting $9.6 billion in 2008 sales, up from $9.4 billion in 2007, on 164 million scrips, up from 160 million. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.